TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1.Chronic hepatitis B.(Hepatitis B surface antigen positive for more than 6 months or having evidence of chronic hepatitis B virus infection).~* 2.Defined by an acute deterioration in transaminase greater than or equal to 5 times upper normal limit over14 days.~* 3.Development of jaundice (serum bilirubin greater than or equal to 10mg/dl).~* 4.Development of coagulopathy(PTA≤40% or INR≥1.5 ).~* More than one of the 5-8 criteria：~* 5.Development of hepatic encephalopathy.~* 6.Development of hepatorenal syndrome.~* 7.Hepatic narrowing progressively.~* 8.Development of massive ascites or peritonitis.~* 9. Willing to provide informed consent and comply with the test requirements~Exclusion Criteria:~* 1.Patients who have hepatocellular carcinoma confirmed by ultrasound/CT/MR.~* 2.Patients who have autoimmune disease (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, etc ) or with abnormal elevation level of autoimmune antibody.~* 3.Model for end-stage liver disease (MELD) score \<17 or \>35.~* 4.Patients with significant co-morbid illnesses such as cardiovascular or respiratory or intrinsic renal diseases which by themselves may have a bearing on the outcome.~* 5.Patients with diseases that researchers consider inappropriate to participate in the study.~* 6.Patients who have disseminated intravascular coagulation.~* 7.Drug allergy.~* 8.Patients with any other contraindications to thymosin alpha1.~* 9.Patients who participated in other clinical trials at the same time.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin-α1 group (Type: EXPERIMENTAL): Patients receive treatment based on standard Therapy with additional Thymosin-α1
- control group (Type: NO_INTERVENTION): Patients receive treatment based on standard Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed Letter of Content~* diagnosis of ulcerative colitis (clinical, endoscopic and histologic evidence)~* chronic active and steroid dependent course over at least 4 months (CAI \> 4, EAI \> 4)~Exclusion Criteria:~* infectious colitis~* toxic megacolon~* ulcerative proctitis or less than 20cm inflamed

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The S.M.A.R.T. Project: Stress Management and Resilience Training for Teens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents age14-17 (inclusive) in high school (may turn 18 after enrollment).~* Score of at least 6 on the Quick Inventory Depressive Symptomatology (QIDS). Potential participants must be pre-screened with the QIDS assessment~* Clinical mental health assessment based on the Diagnostic Interview Schedule for Children-IV (DISC-IV) to screen for serious psychiatric illness, including current major depression~* Able to read and communicate in English~* Willing to be randomized to one of the two arms;~* Able to attend 8 weekly, 1.75 hour sessions, as well as complete self-report measures and homework~* Have access to a computer or other internet-enabled device.~Exclusion Criteria:~* Score of at least 6 on the QIDS (pre-screening);~* Suicidality or major depression as determined by Study Psychologist;~* Inability to speak, write, and read English;~* Active substance abuse, defined as active treatment for substance abuse, legal consequences/school suspensions associated with substance use, or ongoing family conflict associated with substance use;~* History of bipolar disorder, schizophrenia, severe autism, or psychiatric hospitalization within the past 2 years;~* Unable or unwilling to attend or participate in group sessions and/or self-report assessments;~* Current or prior participation in another intervention to address depression or psychiatric conditions;~* Prior formal training in mindfulness, such as a mindfulness course.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Mindful Self-Compassion (MFY) (Type: EXPERIMENTAL): An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
- Healthy Lifestyles (HLG) (Type: ACTIVE_COMPARATOR): An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Participants must meet all of the following criteria to be included in this study:~* Chinese healthy adult volunteers (males and females)~* Non-smoking, male or female age ≥18 years and ≤45 years old at the time of obtaining written consent. To be considered non-smokers, participants must have discontinued smoking from screening before first dosing.~* Participants with a Body Mass Index ≥18.5 and \<24.5 kilograms per meters squared at screening~* Participants who undergo screening within 3 weeks before study treatment and are confirmed to be eligible by the investigator~Exclusion Criteria:~Participants who meet any of the following criteria will be excluded from this study:~* Participants who weigh less than 50 kilograms~* Females who are breastfeeding or pregnant at Screening or Baseline~* Females of childbearing potential~* Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks before first dosing~* Evidence of disease that may influence the outcome of the study within 4 weeks before first dosing~* Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of perampanel at Screening~* Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening~* A prolonged QT/corrected QT (QTc) interval (QTc interval for heart rate using Fredericia's formula \>450 milliseconds) as demonstrated by a repeated ECG at Screening or Baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Perampanel single-dose Part: 2 mg group (Type: EXPERIMENTAL): Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
- Perampanel single-dose Part: 4 mg group (Type: EXPERIMENTAL): Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
- Perampanel single-dose Part: 8 mg group (Type: EXPERIMENTAL): Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
- Perampanel multiple-dose Part (Type: EXPERIMENTAL): Participants will receive multiple oral dose of perampanel (2 milligrams per day \[mg/day\] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 6 month history of probably migraine (6 migraine attacks per month)~* Males and women of childbearing potential on a adequate contraception.~Exclusion Criteria:~* Physician diagnosis of migraine; history of triptan or ergot use; history of headache prophylaxis use~* Pregnant and/or nursing mother~* History of cardiovascular disease.~* Uncontrolled hypertension.~* Basilar or Hemiplegic migraine~* History of stroke or transient ischemic attacks (TIA).~* History of epilepsy or treated with anti-epileptics within the past 5 years.~* Impaired hepatic or renal function.~* History of gastrointestinal bleeding or ulceration.~* Allergy or hypersensitivity to Aspirin or any other NSAID.~* Allergy or hypersensitivity to triptans.~* Participated in an investigational drug trial in the previous 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Treximet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years old;~* Diagnosed primary ITP for at least 12 months;~* Had received at least one first-line ITP treatment with no response or recurrence after treatment;~* Had a platelet count \<30×10\^9/L within 48 hours before the first dose;~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;~* Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form.~Exclusion Criteria:~* Had a history of bone marrow stem cell abnormalities or myelodysplastic syndrome other than ITP-specific changes.~* Had arterial thrombosis, or venous thromboembolism; severe cardiovascular diseases; malignant tumors; secondary thrombocytopenia caused by autoimmune diseases.~* Underwent splenectomy within 12 weeks before the first dose;~* Had received ITP treatments (including rescue treatment) within 2 weeks before the first dose;~* Had received romiplostim (Nplate®) or eltrombopag (Revolade®), rhTPO or other agents that stimulate TPO receptors (also known as c-Mpl), and hematopoietic growth factors (HGFs) within 4 weeks before the first dose;~* Had received antineoplastic agents within 8 weeks before the first administration, but when treating ITP with hypomethylating agents (HMA) such as decitabine, a 4-week washout period was acceptable, as judged by the investigator;~* Had received antibody-based therapies within 14 weeks before the first dose; 8) had serum creatinine or total bilirubin \>1.5 upper limit of normal (ULN), alanine transaminase (ALT) or aspartate transaminase (AST) \>3 ULN, hemoglobin \< 100g/L, absolute neutrophil count \<1.5x10\^9/L;~* Had prothrombin time (PT) or prothrombin time-international normalized ratio (PT-INR) or activated partial thromboplastin time (APTT) exceeded 20% of the reference range of normal values.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QL0911 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who were randomized into study N01280 \[NCT00419094\], and completed the 2 week up titration period~Exclusion Criteria:~* Subjects who did not meet the inclusion/exclusion criteria for N01280 \[NCT00419094\]~* Subjects who were discontinued prior to the end of titration period

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Keppra XR (Levetiracetam XR) (Type: EXPERIMENTAL): 1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of nonvalvular atrial fibrillation atrial flutter by electrocardiogram and echocardiography;~* CHA2DS2VASc score equal to or greater than 1;~* already in use of warfarin for at least 2 months;~* during the run-in, at least one of the three (including the baseline) INR results within 2.0 and 3.0 and a difference of INR results at the 3th and 4th week ≤ ±0.8~* signing of Informed Consent Form.~Exclusion Criteria:~* patients with serious contraindications to the use of anticoagulants (significant bleeding, known sensitivity to warfarin);~* women of childbearing age, pregnant or breastfeeding;~* patients with thrombocytopenia;~* patients with hepatic or renal impairment;~* patients with a history of bleeding episodes due to congenital deficiency of coagulation factors;~* patients enrolled in another trial;~* patients initiating treatment with drugs with major interactions or which are contraindicated when used concomitantly with warfarin, according to our list (Annex I).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence A (Type: OTHER): Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2
- Sequence B (Type: OTHER): Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2
- Sequence C (Type: OTHER): Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®
- Sequence D (Type: OTHER): Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1
- Sequence E (Type: OTHER): Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1
- Sequence F (Type: OTHER): Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a documented history of seasonal allergic rhinitis symptoms that flare up during the study season~* Patient is a nonsmoker and has been a nonsmoker for at least 1 year~* Patient is in good general health~Exclusion Criteria:~* Patient is hospitalized~* Patient is a woman who is less than 8 weeks postpartum or is breast-feeding~* Patient intends to move or vacation away during the study~* Patient has had any major surgery within 4 weeks of study start~* Patient is a current or past abuser of alcohol or illicit drugs~* Patient has been treated in an emergency room for asthma in the past month~* Patient had an upper respiratory infection with in 3 weeks prior to study start

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): montelukast
- 2 (Type: EXPERIMENTAL): loratadine
- 3 (Type: PLACEBO_COMPARATOR): placebo
- 4 (Type: EXPERIMENTAL): montelukast/loratadine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Have at least 6 months history of GERD~* Continuously treated during the last 4 weeks before enrolment with daily optimized unchanged PPI therapy for any GERD indication~Exclusion Criteria:~* Patients that have not experienced any GERD symptom improvement at all during PPI treatment~* Prior surgery of the upper gastrointestinal tract.~* Subject who have any of the following conditions or diseases: Heart disease, Angina, Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 60 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 60 mg bid
- 120 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 120 mg bid
- 180 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 180 mg bid
- 240 mg (Type: EXPERIMENTAL): PPI+lesogaberan (AZD3355) 240 mg bid
- Placebo (Type: PLACEBO_COMPARATOR): PPI+ Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Milk Proteins on Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy female and male Caucasians~* Age between 30 and 70 years at Day 01 of the study~* Body Mass Index (BMI) 18 - 32 kg/m2~* Blood pressure: SBP 120-139 mmHg/DBP 80-89 mmHg (pre-hypertension) or SBP 140-159/DBP 90-99 mmHg (stage 1 hypertension)~* Voluntary participation~* Having given their written informed consent~* Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years~* Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned~Exclusion Criteria:~* Having a history of medical or surgical events that may significantly affect the study outcome, including cardiovascular disease or systolic blood pressure ≥ 160 mm Hg after repeated measurements~* Any concomitant medication, with the exception of paracetamol, that may influence the outcome of the study~* Intolerance or allergy to milk products~* Not willing to give up consumption of \>1 fermented dairy product per day~* Alcohol consumption \> 28 units/week for males or \> 21 units/week for females women)~* Smoking~* Reported unexplained weight loss or weight gain of \> 2 kg in the month prior to pre-study screening or during the study~* Reported slimming or medically prescribed diet~* Reported vegan, vegetarian or macrobiotic life-style~* Participation in night shift work~* Pregnant or lactating or wishing to became pregnant in the period of the study~* Not having a general practitioner~* Not willing to accept information-transfer concerning participation in the study, or information regarding a subject's health to and from a subject's general practitioner.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with osteoarthritis or rheumatoid Arthritis with or at risk of developing cardiovascular disease and who require and eligible for chronic, daily therapy with an NSAID to control arthritis sign and symptoms.~Exclusion Criteria:~* Subjects have had a recent cardiovascular event, unstable cardiovascular conditions, or any major surgery (cardiac or non-cardiac) within 3 months prior to randomization;~* Subjects with medical or laboratory abnormality that would make the subject inappropriate for entry into this trial~* Subjects require treatment with aspirin \> 325 mg /day~* Subjects with known hypersensitivity to celecoxib, ibuprofen, naproxen, aspirin or esomeprazole, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- celecoxib (Type: EXPERIMENTAL): subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
- ibuprofen (Type: ACTIVE_COMPARATOR): subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
- naproxen (Type: ACTIVE_COMPARATOR): subject receives naproxen and dummy (placebo) celecoxib and ibuprofen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete